HCL cases, which all carried the BRAF V600E mutation, had distinctive sensitivity to BRAF and MEK inhibition (Supplemental Figure 17D), whereas in BRAF-mutated CLL, the response to BRAF inhibition was less pronounced. The gene discussed is MAP2K7; the disease is B-cell chronic lymphocytic leukemia.